Tag:
stent
Latest Headlines
Latest Headlines
Medtronic's spinal tools launch; Endurant stent excels
Medtronic ($MDT) is heralding some hopeful news this week from its spinal and stent business lines.
FDA knocks Stryker's Wingspan stent
Stryker is facing a sobering FDA report that points to the company's Wingspan stent as being more damaging than helpful in some cases and of neutral benefit in others, according to a Bloomberg story.
Stent advances expected to prop up European market
First, the bad news: The overall European coronary stent market is expected to dip to about $490 million by 2016, even with growth in procedure numbers. That market number will be the result of a
Boston Sci boasts of positive study results with Epic stent system
A trial of Boston Scientific's ( $BSX ) Epic self-expanding nitinol stent system met its primary endpoints, signaling a win for the company as it attempts to get FDA clearance for the product. The
FDA requires Boston Scientific to caution docs on stent problem
The FDA is evaluating reports about a rare but serious problem--known as longitudinal stent deformation--associated with Boston Scientific's ( $BSX ) Promus Element heart stents and is requiring the
FDA to investigate stent shrinkage
The FDA is looking at a problem in a newer class of heart stents that causes the devices to shrink--or lengthen--after implantation. The events have been seen most frequently in Boston Scientific's
Medtronic's Resolute DES shows good results in diabetics
Medtronic's ( $MDT ) Resolute drug-eluting stent showed strong results in diabetic patients with coronary artery disease through one year of follow-up, according to data presented this week at the
Medtronic beats Boston Scientific in drug-eluting stent studies
Medtronic's Resolute drug-eluting stent beat out rival Boston Scientific's Taxus DES in late lumen loss after 8 months in a study that helps pave the way for Japanese regulatory approval for
Elixir Medical gets good news in EU on novolimus DES
Sunnyvale, CA-based Elixir Medical has received the CE Mark for its DESyne drug-eluting coronary stent system for the treatment of coronary artery disease. The company plans to launch the DESyne
Study: Patients in stroke device trials don't resemble typical patients
Participants in tests done as part of postmarketing surveillance (PMS) studies for carotid artery stenting to prevent strokes tend to be healthier than those who typically receive the devices,
